Product Information
DOXYCYCLINE 25 MG/5 ML SUSP is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.2304 per ML under NDC 68180065701. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Mar 18, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/5mL
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180065701
Classification
Generic
Dosage Form
FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXYCYCLINEApproval Type
Generic (ANDA)
FDA Application
ANDA201678FDA Approved
3/18/2013
TE Code
AB
On Market Since
6/11/2013
Pharmacological Classes
Price Statistics
The NADAC for DOXYCYCLINE 25 MG/5 ML SUSP has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 25.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2304 per ML |
|---|---|
| All-time high | $0.3267 (Oct 12, 2016) |
| All-time low | $0.1814 (Nov 20, 2024) |
| 52-week high | $0.2341 |
| 52-week low | $0.2164 |
| Median price | $0.2699 |
| Average price | $0.2652 |
| Largest weekly change | +32.2% (Nov 20, 2019) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the DOXYCYCLINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
DOXYCYCLINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tetracycline-class Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXYCYCLINE 25 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for DOXYCYCLINE 25 MG/5 ML SUSP, manufactured by Lupin Pharmaceuticals Inc., is $0.2304 per ML (NDC 68180065701), effective Sep 30, 2026.
How has the price of DOXYCYCLINE 25 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for DOXYCYCLINE 25 MG/5 ML SUSP has declined 25.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DOXYCYCLINE 25 MG/5 ML SUSP?
Since Nov 28, 2013, the NADAC for DOXYCYCLINE 25 MG/5 ML SUSP has ranged from a low of $0.1814 (Nov 20, 2024) to a high of $0.3267 (Oct 12, 2016), with a median of $0.2699 per ML.
Are there cheaper alternatives to DOXYCYCLINE 25 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of DOXYCYCLINE 25 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOXYCYCLINE 25 MG/5 ML SUSP?
DOXYCYCLINE 25 MG/5 ML SUSP (NDC 68180065701) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.